ProMIS Neurosciences Inc. PMN 深滬

已收盤 02-06 16:00:00 美东时间

12.73

-0.370

-2.82%

華盛通

立即下載

最高14.00
今開14.00
成交量 6.15万股
最低 12.70
昨收 13.10
總市值 2740.06万
52周最高 39.75
市盈率 ^靜 4.85
換手率 2.86%
52周最低 6.51
委比 56.52%
總股本 215.24万
歷史最高 245.00
量比 0.04
振幅 9.92%
歷史最低 6.72
每手 1
風險率 4.26%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Guggenheim Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $35

Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $125 to $35.

02-06 22:56
ProMIS Neurosciences shares are trading higher. The company announced a $175 million private placement financing.

ProMIS Neurosciences shares are trading higher. The company announced a $175 mi...

01-30 21:08
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences Inc. announced the completion of a $175 million financing to extend its cash runway into 2028. The proceeds aim to complete its Phase 1b Alzheimer’s disease (AD) study and support key clinical milestones. Blinded 6-month top-line data is expected mid-2026, with 12-month data toward year-end 2026. The financing was led by Janus Henderson and Ally Bridge Group, with participation from new and existing investors, including Deep ...

01-30 13:00
ProMIS Neurosciences Completes Enrollment Of 144 Patients In PRECISE-AD Phase 1b Clinical Trial, Evaluating PMN310, Therapeutic Antibody Candidate For Treatment Of AD

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's diseaseClear and near-term value inflection points, with blinded 6-month interim data expected

2025-12-18 20:33
ProMIS Highlights Alzheimer's & Dementia Publication Linking Preferential Targeting Of Soluble Toxic Aβ Oligomers To Efficacy And Lower ARIA Risk

Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer's

2025-12-10 20:46
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元

今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元

2025-12-02 09:50
ProMIS Neurosciences Highlights Plasma pTau As Early Predictor In PRECISE-AD Trial, Publication Reinforces Biomarker-Driven Design Ahead of Q2 2026 Interim Readout

Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trialProMIS on track to leverage new plasma pTau insights with

2025-12-01 20:37
ProMIS Neurosciences Announces 1-For-25 Reverse Stock Split, Effective Nov. 28

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that its board

2025-11-24 21:01
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价

今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元

2025-11-24 11:23
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Kazia Therapeutics (NASDAQ:KZIA) shares increased by 51.6% to $8.73 du...

2025-11-19 20:05

派息除權日	每股總股息	派息日期
2007-05-22	0.04	2007-06-01
2007-04-20	0.04	2007-05-01
2007-03-21	0.04	2007-04-02
2007-02-16	0.04	2007-03-01
2007-01-22	0.04	2007-02-01
2006-12-20	0.05	2007-01-02
2006-11-21	0.04	2006-12-01
2006-10-20	0.04	2006-11-01
2006-09-20	0.04	2006-10-02
2006-08-21	0.04	2006-09-01
2006-07-20	0.04	2006-08-01
2006-06-21	0.04	2006-07-03
2006-05-22	0.04	2006-06-01
2006-04-20	0.04	2006-05-01
2006-03-22	0.04	2006-04-03
2006-02-16	0.04	2006-03-01
2006-01-20	0.04	2006-02-01
2005-12-20	0.04	2006-01-03
2005-11-21	0.04	2005-12-01
2005-10-20	0.04	2005-11-01
2005-09-21	0.04	2005-10-03
2005-08-22	0.04	2005-09-01
2005-07-20	0.04	2005-08-01
2005-06-22	0.04	2005-07-01
2005-05-20	0.05	2005-06-01
2005-04-20	0.05	2005-05-02
2005-03-22	0.05	2005-04-01
2005-02-18	0.05	2005-03-01
2005-01-20	0.05	2005-02-01
2004-12-21	0.06	2005-01-03
2004-11-22	0.06	2004-12-01
2004-10-20	0.06	2004-11-01
2004-09-22	0.06	2004-10-01
2004-08-20	0.06	2004-09-01
2004-07-21	0.06	2004-08-02
2004-06-22	0.06	2004-07-01
2004-05-20	0.06	2004-06-01
2004-04-21	0.06	2004-05-03
2004-03-22	0.06	2004-04-01
2004-02-20	0.06	2004-03-01
2004-01-21	0.06	2004-02-02
2003-12-22	0.06	2004-01-02
2003-11-20	0.06	2003-12-01
2003-10-22	0.06	2003-11-03
2003-09-22	0.06	2003-10-01
2003-08-20	0.06	2003-09-02
2003-07-22	0.06	2003-08-01
2003-06-20	0.06	2003-07-01
2003-05-21	0.06	2003-06-02
2003-04-22	0.06	2003-05-01
2003-03-20	0.06	2003-04-01
2003-02-20	0.06	2003-03-03
2003-01-16	0.06	2003-02-03
2002-12-18	0.07	2003-01-02
2002-11-18	0.06	2002-12-02
2002-10-17	0.06	2002-11-01
2002-09-18	0.06	2002-10-01
2002-08-16	0.06	2002-09-03
2002-07-18	0.06	2002-08-01
2002-06-18	0.06	2002-07-01
2002-05-16	0.06	2002-06-03
2002-04-18	0.06	2002-05-01
2002-03-18	0.06	2002-04-01
2002-01-17	0.06	2002-02-01
2001-12-18	0.06	2002-01-02
2001-11-16	0.06	2001-12-03
2001-10-18	0.06	2001-11-01
2001-09-18	0.06	2001-10-01
2001-08-16	0.06	2001-09-04
2001-07-18	0.06	2001-08-01
2001-06-18	0.06	2001-07-02
2001-05-17	0.06	2001-06-01
2001-04-18	0.06	2001-05-01
2001-03-16	0.06	2001-04-02
2001-02-15	0.06	2001-03-01
2001-01-18	0.06	2001-02-01
2000-12-18	0.07	2001-01-02
2000-11-16	0.07	2000-12-01
2000-10-18	0.07	2000-11-01
2000-09-18	0.07	2000-10-02
2000-08-17	0.07	2000-09-01
2000-07-18	0.07	2000-08-01
2000-06-16	0.07	2000-07-03
2000-05-18	0.07	2000-06-01
2000-04-18	0.07	2000-05-01
2000-03-16	0.07	2000-04-03
2000-02-17	0.07	2000-03-01
2000-01-18	0.07	2000-02-01
1999-12-16	0.07	2000-01-03
1999-11-18	0.07	1999-12-01
1999-10-18	0.07	1999-11-01
1999-09-16	0.07	1999-10-01
1999-08-18	0.07	1999-09-01
1999-07-16	0.07	1999-08-02
1999-06-17	0.07	1999-07-01
1999-05-18	0.07	1999-06-01
1999-04-16	0.07	1999-05-03
1999-03-18	0.07	1999-04-01
1999-02-18	0.07	1999-03-01
1999-01-15	0.07	1999-02-01
1998-12-17	0.07	1999-01-04
1998-11-18	0.07	1998-12-01
1998-10-16	0.07	1998-11-02
1998-09-17	0.07	1998-10-01
1998-08-18	0.07	1998-09-01
1998-07-16	0.07	1998-08-03
1998-06-18	0.07	1998-07-01
1998-05-18	0.07	1998-06-01
1998-04-16	0.07	1998-05-01
1998-03-18	0.07	1998-04-01
1998-02-18	0.07	1998-03-02
1998-01-15	0.07	1998-02-02
1997-12-18	0.07	1998-01-02
1997-11-18	0.07	1997-12-01
1997-10-16	0.07	1997-11-03
1997-09-18	0.07	1997-10-01
1997-08-18	0.07	1997-09-02
1997-07-17	0.07	1997-08-01
1997-06-18	0.07	1997-07-01
1997-05-16	0.07	1997-06-02
1997-04-17	0.07	1997-05-01
1997-03-18	0.07	1997-04-01
1997-02-18	0.07	1997-03-03
1997-01-15	0.07	1997-02-03
1996-12-18	0.07	1997-01-02
1996-11-18	0.07	1996-12-02
1996-10-17	0.07	1996-11-01
1996-09-18	0.07	1996-10-01
1996-08-16	0.07	1996-09-03
1996-07-18	0.07	1996-08-01
1996-06-18	0.07	1996-07-01
1996-05-16	0.07	1996-06-03
1996-04-18	0.07	1996-05-01
1996-03-18	0.07	1996-04-01
1996-02-15	0.07	1996-03-01
1996-01-18	0.07	1996-02-01
1995-12-18	0.07	1996-01-02
1995-11-16	0.08	1995-12-01
1995-10-18	0.08	1995-11-01
1995-09-18	0.08	1995-10-02
1995-08-17	0.08	1995-09-01
1995-07-19	0.08	1995-08-01
1995-06-16	0.08	1995-07-03
1995-05-16	0.08	1995-06-01
1995-04-13	0.08	1995-05-01
1995-03-14	0.08	1995-04-03
1995-02-14	0.08	1995-03-01
1995-01-13	0.08	1995-02-01
1994-12-14	0.17	1995-01-03
1994-11-15	0.08	1994-12-01
1994-10-14	0.08	1994-11-01
1994-09-14	0.08	1994-10-03
1994-08-16	0.08	1994-09-01
1994-07-14	0.08	1994-08-01
1994-06-14	0.08	1994-07-01
1994-05-16	0.08	1994-06-01
1994-04-14	0.08	1994-05-02
1994-03-15	0.08	1994-04-04
1994-02-15	0.08	1994-03-01
1994-01-13	0.08	1994-02-01
1993-12-14	0.23	1994-01-03
1993-11-16	0.08	1993-12-01
1993-10-14	0.08	1993-11-01
1993-09-14	0.08	1993-10-01
1993-08-16	0.08	1993-09-01
1993-07-14	0.08	1993-08-02
1993-06-15	0.08	1993-07-01
1993-05-14	0.08	1993-06-01
1993-04-14	0.08	1993-05-03
1993-03-16	0.08	1993-04-01
1993-02-16	0.08	1993-03-01
1993-01-13	0.08	1993-02-01

公司名稱	ProMIS Neurosciences, Inc.
行業分類	Biotechnology
業務描述	ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

ProMIS Neurosciences Inc. PMN 深 滬

12.73

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

ProMIS Neurosciences Inc. PMN 深滬